Skip to Content

Treatment after JAKi in patients with rheumatoid arthritis

This study, presented by Professor of Medicine and Rheumatology Janet Pope, highlights the effectiveness of cycling JAK inhibitors (JAKi) of different classes compared with switching to a biological disease-modifying antirheumatic drug (bDMARD) in patients with rheumatoid arthritis (RA) after failure to the first JAKi.

Janet Pope

Få adgang til artiklen

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top